BiotechTube

Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Pulmonary Fibrosis

Conditions

Idiopathic Pulmonary Fibrosis

Trial Timeline

Jan 20, 2020 → Dec 23, 2021

NCT ID
NCT04233814

About Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo

Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo is a phase 1 stage product being developed by Rein Therapeutics for Idiopathic Pulmonary Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04233814. Target conditions include Idiopathic Pulmonary Fibrosis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04233814Phase 1Completed

Competing Products

20 competing products in Idiopathic Pulmonary Fibrosis

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
85
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
Zimura + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 2
52
Rituximab + cyclosporineSun PharmaceuticalPhase 3
77
E5501EisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
33
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
77
Placebo + Avatrombopag tabletsEisaiPhase 2
52
PerampanelEisaiPre-clinical
23
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oralEisaiPhase 1
33

Other Products from Rein Therapeutics

LTI-03 + PlaceboPhase 2
44
LTI-01 + PlaceboPhase 2
44
LTI-03 + PlaceboPhase 1
25